KaloBios Pharmaceuticals (NASDAQ:KBIO) is a small-cap company focused on developing patient-targeted, first-in-class monoclonal antibodies using its proprietary Humaneered technology platform, with the intent to significantly improve the lives of seriously ill patients with difficult-to-treat diseases. Currently, the company's primary clinical focus is treating infectious and respiratory diseases and cancer. KaloBios has two antibodies in Phase II clinical testing for the treatment of severe/persistent asthma and cystic fibrosis (CF) and prevention of ventilation-associated pneumonia (VAP). It also has a third antibody in Phase I clinical testing for hematological malignancies.
The Company's Pipeline:
1. Humaneered technology - The Humaneered technology forms the basis of the company's drug discovery and development. The technology first uses conventional methods to identify initial antibody...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|